• Golden Eye 0.1% w/v Eye Drops
    Golden Eye Drops Solution
  • Hypromellose 0.3% Eye Drops
    Hypromellose Eye Drops - For Dry Eyes
  • Optrex Bloodshot Eye Drops
    Optrex Bloodshot Eye Drops-ads
  • Viscotears Gel For Dry Eye
    Viscotears Gel For Dry Eye Treatment 10g
  • Golden Eye Chloramphenicol Eye
    Golden Eye Chloramphenicol Eye Ointment
  • Spatone Apple Liquid Iron
    Spatone Apple Liquid Iron Supplement-banner
  • Holland & Barrett Gentle Iron 20mg
    Holland & Barrett Gentle Iron 20mg 90 Capsules-banner
  • Vitabiotics Feroglobin Capsules
    Vitabiotics Feroglobin Capsules-banner

Global Cancer Drug Spending Hits $100 billion in 2014: IMS Health

Bill Berkrot
medicine_cabinet-cancer

Worldwide spending on cancer medicines reached $100 billion in 2014, an increase of 10.3 percent from 2013 and up from $75 billion five years earlier, according to IMS Health’s Global Oncology Trend Report released on Tuesday.

The $100 billion, which represents 10.8 percent of all drug spending globally and includes supportive care drugs to address things like nausea and anemia, was driven by expensive newer treatments in developed markets, IMS found. That is seen rising to $117 billion to $147 billion in 2018, IMS forecast, a compound annual growth rate of 6-8 percent.

Waves of similar drugs, such as those that spur the immune system to fight cancer being developed by Bristol-Myers Squibb, Merck, Roche, AstraZeneca and others, will create competition that could help moderate costs.

“We’re in for a period of intense competition among alternative treatments, which is a different dynamic than we’ve seen in the past where the progress has been a little slower and individual drugs had a little more time,” said Murray Aitken, executive director of IMS Institute for Healthcare Informatics, which compiled the report.

The United States accounted for 42.2 percent of total spending, followed by the top-five European markets, comprised of Germany, France, Britain, Spain and Italy. In the big-five European markets, oncology spending rose to 14.7 percent of total drug spending, up from 13.3 percent in 2010, while U.S. oncology spending increased to 11.3 percent of the total from 10.7 percent over the same period.

Medicines that target a specific protein or genetic mutation, as opposed to chemotherapies, now account for almost half of total U.S. cancer drug spending, IMS, which tracks prescription drug data for the industry, found.

Forty-five new cancer drugs were launched between 2010 and 2014. But patients in no country had access in 2014 to all 37 launched between 2009 and 2013. The broadest access was seen in the United States, Germany and Britain, while fewer than half the new drugs were available in South Korea, Spain or Japan, the report said.

Five-year survival rates for many cancers are rising, the report found, with new immunotherapies, such as Merck’s Keytruda and Bristol’s Opdivo, holding the promise of improved survival with fewer side effects. “$100 billion is a significant proportion of total spending on medicines and total healthcare costs, but it’s part of the healthcare system that’s producing great results and bringing great benefit to patients,” Aitken said.

Published: May 5, 2015. By Bill Berkrot; Editing by Diane Craft
Copyright © 2015 Thomson Reuters Foundation

About Black Patient

Health Information & Support │www.blackpatient.com │ www.twitter.com/blackpatient │ www.facebook.com/blackpatient

Leave a Reply

Subscribe to SMS

Get text messages such as vaccination reminders, antenatal/postnatal tips, health alerts, disease prevention and more straight to your mobile phone.

Opt out from SMS / Email